CRISPR-Cas12a Gene Editing of <i>HBG1</i> and <i>HBG2</i> Promoters to Treat β-Thalassemia
Article Details
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
Authors (14)
Haydar Frangoul
Sarah Cannon Research Institute at the Children’s Hospital at TriStar Centennial, Nashville
Rabi Hanna
Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland
Mark C. Walters
UCSF Benioff Children’s Hospital, Oakland, CA
Roy L. Kao
Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis
Clinton Carroll
Sarah Cannon Research Institute, Nashville
Meghann McManus
Sarah Cannon Research Institute, Nashville
Kai-Hsin Chang
Department of Chemistry
Michael C. Jaskolka
Editas Medicine, Cambridge, MA
Keunpyo Kim
Editas Medicine, Cambridge, MA
Qifeng Yu
Nnenna Badamosi
Editas Medicine, Cambridge, MA
Baisong Mei
Editas Medicine, Cambridge, MA
Olubunmi Afonja
Editas Medicine, Cambridge, MA
Alexis Thompson